---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-000958"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:34:44.010084+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# SELLAS Life Sciences terminates $50M ATM sales agreement with Cantor Fitzgerald

## Summary
- Mutual termination of Controlled Equity Offering Sales Agreement dated April 16, 2021.
- ATM program allowed up to $50M in common stock sales; prior termination, 1,294,814 shares sold for ~$10.5M net.
- Related prospectus supplement filed in 2021 also terminated effective immediately.
- Company may explore alternative financing options going forward.

## SEC filing metadata
- accession: 0001104659-24-000958
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465924000958/0001104659-24-000958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465924000958/tm241849d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-000958
- JSON: https://secwatch.observer/filing/0001104659-24-000958.json
- Plain text: https://secwatch.observer/filing/0001104659-24-000958.txt

## Key facts
- Material Agreements
  SELLAS Life Sciences Group, Inc. terminated Sales Agreement with Cantor Fitzgerald & Co. valued at up to an aggregate of $50,000,000 (effective 2024-01-02).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: up to an aggregate of $50,000,000
  - Effective: 2024-01-02
  source text: On January 2, 2024, SELLAS Life Sciences Group, Inc. (the “Company”) and Cantor Fitzgerald & Co. (the “Agent”) mutually agreed to terminate the Controlled Equity Offering SM Sales Agreement, dated April 16, 2021 (“Sales Agreement”), pursuant to which the Company could from time to time offer and sell up to an aggregate of $50,000,000 of shares of its common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000110465924000958/0001104659-24-000958-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.